Tokai Pharmaceuticals Announces Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
BMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 10:44 AM EDTBMO Capital downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform with a price target of $2.00.
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... MoreBMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 10:43 AM EDTBMO Capital downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform with a price target of $1.70 (from $11.00) following the discontinuation of ARMOR3-SV.
Analyst Do Kim commented, "We are downgrading Tokai (TKAI) shares to Market Perform from Outperform, following the... More
Stifel Downgrades Tokai Pharmaceuticals (TKAI) to Hold
July 26, 2016 9:45 AM EDTStifel downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Buy to Hold after ARMOR3 stopped.
Analyst Thomas Shrader commented, "The ARMOR3 DMC has informed Tokai that the trial is unlikely to reach its rPFS endpoint (ruling of futility). Essentially no other data was... More
Janney Montgomery Scott Downgrades Tokai Pharmaceuticals (TKAI) to Neutral
July 26, 2016 8:50 AM EDTJanney Montgomery Scott downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Buy to Neutral with a price target of $2.00 (from $12.00).
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... MoreWells Fargo Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
July 26, 2016 8:23 AM EDTWells Fargo downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
... More